



# Xience PRIME

Everolimus Eluting  
Coronary Stent System

**Safety.  
First.**

## XIENCE: proven\* performance in complex patients





### Data in complex patient populations including:<sup>†</sup>

- ✓ **Left Main**
- ✓ **AMI**
- ✓ **ACS**
- ✓ **Bifurcations**
- ✓ **Renal Insufficiency**
- ✓ **Multivessel Disease**
- ✓ **Diabetes**
- ✓ **CTOs**
- ✓ **Grafts**
- ✓ **Restenotic Lesions**
- ✓ **Ostial Lesions**

<sup>†</sup> All statements being made and data shown are reflective of the entire patient population in the study and are not representative of any specific lesion type.

## Platinum: 1 Head-to-Head comparison in low risk patient population



“Longer-term follow-up, and in more complex lesions, is required for comprehensive evaluation between these two devices.”

– As published in JACC, April 2011


# XIENCE: Designed for Outstanding Deliverability with Optimal Scaffolding and Radial Strength

## XIENCE PRIME


### Leverages proven MULTI-LINK heritage

3 link design for uniform scaffolding, uniform drug distribution and minimal plaque prolapse

- Peak-to-Valley design



- Metal-to-Artery ratio (3.0x18 mm stent) : 13.3%
- L605 Cobalt Chromium




## Promus Element


### New stent design - new alloy

2 link design leads to uneven scaffolding on a bend

- Off-set Peak-to-Peak design




- Metal-to-Artery ratio (3.0x20 mm stent) : 14.5%
- Platinum Chromium



## XIENCE

### Consistent range of radial strength across all sizes



### Tensile Strength of Various Alloys<sup>5</sup>

Alloy	Tensile Strength (MPa)
L605 (Cobalt Chromium)	1000
MP35N (Cobalt Nickel)	990
Pt-Cr (Platinum Chromium)	834
316L (Stainless Steel)	505

### Post-Procedure In-Stent Minimum Lumen Diameter (MLD) – Boston Scientific PLATINUM Trial<sup>6</sup>

<b>XIENCE V</b>	2.54 mm ± 0.44 mm
<b>Promus Element</b>	2.57 mm ± 0.42 mm

p=0.25

As measured in a predinical canine model – Agrawal et al. Biomaterials Vol. 13, 3, 1992. Calculation based on 1mm/Hg = 0.01934 PSL. Test performed by and data on file at Abbott Vascular.

# XIENCE: Designed for Accurate Placement and Apposition

## XIENCE

### Minimal shortening upon deployment for accurate placement

#### XIENCE PRIME\*



1.8% (0.33 mm on 18 mm stent)

\* 3.0 x 18 mm XIENCE PRIME and 3.0 x 20 mm Promus Element deployed to RBP

#### Promus Element\*



7.5% (1.5 mm on 20 mm stent)

## XIENCE

### Designed to simplify sizing: Flexibility to ensure complete vessel wall apposition

Promus Element: 4 stent designs		XIENCE : 2 stent designs		
Limited expansion range		Large expansion range		
Nominal stent inner diameter*	Max. expansion inner diameter*	Nominal stent inner diameter	Max. expansion inner diameter	
			XIENCE V	XIENCE PRIME
2.25	2.75	2.25	3.50	3.25
2.50	3.25	2.50		3.75
2.75	3.50	2.75		
3.00	3.75	3.00	4.50	4.50
3.50	4.25	3.50		
4.00	4.75	4.00		

\*source: IFU

## Promus Element

### Stent designs:



2.25 mm

2.5 – 2.75 mm

3.0 – 3.5 mm

4.0 mm


# Platinum: Simple Patient Population at 1 year

	PLATINUM <sup>4</sup> (N=1530)	COMPARE <sup>7</sup> (N=1800)	RESOLUTE All Comers <sup>8</sup> (N=2292)
AMI	excluded	25%	33.7%
CTO	excluded	4%	17.2%
Bifurcations	excluded	10%	17.7%
LMCA Lesions	excluded	2%	2.5%
SVG Lesions	excluded	2%	2.4%
Ostial Lesions	excluded	19%	NR
Lesions with Thrombus	excluded	24%	4.8%
Calcification	excluded	34%	19.8%

## XIENCE. Safety. First.

### Consistently Low Stent Thrombosis Rates. Trial after Trial.

#### Stent Thrombosis Rates (ARC Definite) in All Comer Populations at 2 Years Published in The Lancet,<sup>6</sup> April 2011



2  
Years

TLR at 2 Years: XIENCE V 5.1%, Endeavor Resolute 5.7%, Biomatrix 6.3%, Cypher 7.1%, Taxus Liberté 5.9%

1. Based on patient numbers from various Abbott and non-Abbott trials. Data on file at Abbott Vascular. 2. Source: Data from SPIRIT FIRST and SPIRIT II trials. 3. Source: Trials registered on clinicaltrials.gov as of Jan. 25, 2011. 4. Source: G Stone et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM trial. JACC. Published online April 4, 2011. Boston Scientific sponsored study. 5. Source: B O'Brien et al. A platinum-chromium steel for cardiovascular stents. Biomaterials. Published online February 23, 2010. Boston Scientific sponsored paper. 6. Silber S et al. Unrestricted randomized use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. The Lancet. Published online April 3, 2011. 7. Dr. Peter Smits, COMPARE 2-year results presentation, TCT 2010. 8. Serruys P. et al. Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary stents. NEJM, 363: 136-146  
\* Data on file at Abbott Vascular.

#### Abbott Vascular International BVBA

Park Lane, Culliganlaan 2B, B-1831 Diegem, Belgium. Tel: 32.2.714.14.11 Fax: 32.2.714.14.12

SPIRIT FIRST, SPIRIT II are Abbott Vascular Sponsored Studies – All Abbott Vascular products in these studies are used in accordance with approved IFU and regulatory requirements. Abbott Vascular does not directly or indirectly promote any off label use and recommends that the IFU is read thoroughly before the use of all devices in this study. COMPARE is an Investigator Sponsored Study. Abbott Vascular does not promote directly or indirectly any out of intended use and recommends that the IFU is read thoroughly before the use of all devices in this study. Resolute All Comers is an Independent all comers trial sponsored by Medtronic. Platinum is a randomized clinical trial sponsored by Boston Scientific.

Products intended for use by or under the direction of a physician. Prior to use, it is important to read the package insert thoroughly for instructions for use, warnings and potential complications associated with use of this device. **Information contained herein is for distribution for Europe, Middle East and Africa ONLY.** Please check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

All drawings are artist's representations only and should not be considered as engineering drawings or photographs. Photo(s) taken by and on file at Abbott Vascular. Tests performed by and data on file at Abbott Vascular.

XIENCE PRIME, MULTI-LINK and XIENCE V are trademarks of the Abbott Group of Companies. BIOMATRIX is a trademark of Biosensors International. Cypher is a trademark of Cordis Corporation. Resolute is a trademark of Medtronic, Inc. Taxus Liberté, PROMUS ELEMENT are trademarks of Boston Scientific.

www.XiencePrime.com

©2011 Abbott. All rights reserved. 1-EH-1-1436-01 09/2011

